DV
Dividend Vision

AMLX — Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (AMLX)

Total return is 19.7% over the past 4.6 years, 57.3 points behind SPY at 77.0%. Its deepest 1-year drawdown was 30.6%.

This appears to be a single-stock equity holding rather than a diversified ETF, consisting of shares in Amylyx Pharmaceuticals, a healthcare company. As a concentrated position in one pharmaceutical stock, it carries higher volatility risk than a traditional diversified fund and does not currently pay distributions. The lack of an expense ratio and missing fund characteristics suggest this may be a special purpose vehicle or requires additional verification of its ETF structure and current operational status.

AMLX key facts

Asset type
Stock
Asset class
Equity
Inception date
01/07/2022
Distribution frequency
None
Last close
$21.63
Market cap
$2,410,080,512
Average volume
1588794.0
Beta
-0.205
Payout ratio
0.0
Forward P/E
2.7739
EPS
$-1.41